Kura Oncology’s (KURA) Market Outperform Rating Reiterated at Citizens Jmp

Citizens Jmp reiterated their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a report published on Monday,Benzinga reports. The brokerage currently has a $24.00 price target on the stock.

KURA has been the subject of a number of other reports. Oppenheimer set a $24.00 price target on Kura Oncology in a research note on Thursday, May 28th. Wedbush lifted their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Jefferies Financial Group set a $24.00 price objective on shares of Kura Oncology in a report on Thursday, May 28th. Wells Fargo & Company set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th. Finally, Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a report on Monday. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.40.

Kura Oncology Stock Down 3.9%

Shares of Kura Oncology stock opened at $13.06 on Monday. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. Kura Oncology has a 12 month low of $7.36 and a 12 month high of $13.90. The business has a fifty day simple moving average of $10.74 and a 200 day simple moving average of $9.58. The stock has a market cap of $1.16 billion, a PE ratio of -3.88 and a beta of 0.38.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The business had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Research analysts predict that Kura Oncology will post -3.23 EPS for the current year.

Insiders Place Their Bets

In other Kura Oncology news, CEO Troy Edward Wilson purchased 100,000 shares of the stock in a transaction on Monday, August 24th. The stock was bought at an average cost of $12.39 per share, for a total transaction of $1,239,000.00. Following the completion of the acquisition, the chief executive officer directly owned 479,194 shares of the company’s stock, valued at $5,937,213.66. The trade was a 26.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Teresa Brophy Bair sold 31,487 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $12.63, for a total value of $397,680.81. Following the sale, the insider directly owned 195,444 shares in the company, valued at approximately $2,468,457.72. This represents a 13.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 120,761 shares of company stock valued at $1,283,346 over the last ninety days. 7.60% of the stock is owned by insiders.

Institutional Trading of Kura Oncology

Several hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its holdings in shares of Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after purchasing an additional 348,127 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its position in Kura Oncology by 69.7% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock valued at $6,240,000 after purchasing an additional 233,633 shares in the last quarter. UBS Group AG grew its position in Kura Oncology by 118.3% in the fourth quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock valued at $11,014,000 after purchasing an additional 574,455 shares in the last quarter. Nan Fung Trinity HK Ltd. increased its stake in Kura Oncology by 317.9% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock valued at $10,025,000 after buying an additional 734,000 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in Kura Oncology by 285.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company’s stock valued at $1,291,000 after buying an additional 117,650 shares during the last quarter.

More Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: CEO Troy Wilson reportedly purchased 100,000 shares for approximately $1.24 million, a sizable open-market investment that investors may interpret as confidence in Kura’s growth prospects. Kura Oncology shares jump after CEO buys $1.24 million of stock
• Positive Sentiment: Analysts continue to express optimism, with Citizens JMP reiterating a “Market Outperform” rating. Broader coverage shows a consensus “Moderate Buy” rating and an average price target of $25.40, materially above recent trading levels. Citizens JMP reiterates Market Outperform rating
• Positive Sentiment: Kura’s commercial outlook is being supported by KOMZIFTI (ziftomenib), which generated $9.1 million in net product revenue over its first two quarters, including 57% sequential growth. Potential expansion into first-line acute myeloid leukemia could substantially increase the addressable market. Phase 1b data are expected in the second half of 2026, with Phase 3 KOMET-017 topline results targeted for 2028. Kura Oncology: Strong Buy and ziftomenib AML expansion prospects
• Positive Sentiment: Recent earnings exceeded expectations: quarterly revenue was $20.87 million versus a $20.16 million consensus estimate, while the per-share loss was narrower than forecast. Institutional ownership also increased, including a large position expansion by California State Teachers’ Retirement System.
• Neutral Sentiment: The company remains unprofitable, with analysts expecting a full-year loss, so valuation remains dependent on continued KOMZIFTI sales growth and successful clinical development.
• Negative Sentiment: Insider Brian Powl sold 4,345 shares worth approximately $51,662. The sale was relatively small and reduced his holdings by 2.5%, but it contrasts with the CEO’s much larger purchase. Kura Oncology insider share sale

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.